Вісник серцево-судинної хірургії 2018 ішемічна хвороба серцяCoronary revascularization provides symptomatic relief from coronary artery disease (CAD) and improves short and long-term outcomes in patients with CAD. The optimal revascularization strategy is still controversial among interventional and conventional approaches for coronary revascularization, although coronary artery bypass grafting (CABG) remains the standard of care for patients with three-vessel or left main coronary artery disease, since the use of CABG, as compared with percutaneous interventions (PCI), resulted in lower rates of the combined end point of major adverse cardiac or cerebrovascular events (MACE) at 1 year according to SYNTAX study (SYNergy Between PCI With TAXus and Cardiac Surgery). The optimal revascularization strategy should combine a minimally invasive surgical procedure that reduces perioperative risk, while maximizing long-term patency of conduit for CABG along with patient's survival rates.Hybrid coronary revascularization (HCR) was first introduced in 1996 [1] as a promise to full coronary artery revascularization minimizing surgical trauma and adverse cardiovascular events. The initial concept was launched by Dr. Gianni from Imperial college of London and included small number of patients, who received favorable outcomes in terms of hospital stay, duration of extubation and 6-month period survival. The hybrid approach refers to the combination of CABG and PCI, namely providing anastomosis of left internal mammary artery (LIMA) to left anterior descending artery (LAD), typically via minimally invasive technique and PCI for remaining (non-LAD) vessels.The rationale for HCR lies in the well-established survival benefit conferred by LIMA-to-LAD grafts and the use of new DES-stent platforms featuring low stent restenosis and thrombosis rates compared with venous graft stenosis and occlusion rates [2]. The superior patency of LIMAto-LAD graft provides prophylaxis against future proximal LAD lesions, which translates into better event-free survival and relief of angina. The benefits of bypassing other non-LAD coronary vessels are much less clear. Conduits for a non-LAD vessel may include other arterial grafts (complete arterial revascularization), but the saphenous vein is by far the most commonly used. A major limitation of CABG with great saphenous vein grafts (GSV) lies in the high graft failure rates with reports ranging from 13% to 29% at 1 year and up. Newer drug-eluting stent (DES) platforms with (e.g., everolimus-eluting stents (EES) or zotarolimus-eluting stents (ZES) or without (bioresorbable polymer-based or polymer-free stents) durable polymers show favorable outcomes, with 1-year target lesion revascularization (TLR) rates as low as 3% to 3.25% [4]. Even in high-risk patients and complex lesions, ZES and EES maintain very low 1-year TLR rates of 4.4% and 4%, respectively [5]. Thus, PCI and stenting provide strong competition for SVG revascularization because, unlike an LIMA-LAD graft, disease progression in the proxi...